索托维单抗与莫诺拉韦预防社区新冠重症结局的比较效果:OpenSAFELY平台观察性队列研究
该研究基于OpenSAFELY平台英国电子健康记录,比较社区高危新冠成人患者中索托维单抗与莫诺拉韦预防28天内住院或死亡的效果。
要点
- 社区高危新冠成人患者中,索托维单抗较莫诺拉韦显著降低28天内住院或死亡风险。
- 调整后HR为0.54(95%CI 0.33-0.88,P=0.01),倾向评分加权模型结果一致。
- 奥密克戎BA.2流行期的探索性分析结果相似。
核心结论
- 在英格兰社区高危新冠成人患者的常规诊疗中,接受索托维单抗治疗者较莫诺拉韦治疗者的新冠重症结局风险更低。
主要发现
- 全部6020例患者平均年龄52岁(标准差16),59%为女性,89%为白人,88%接种过三剂及以上新冠疫苗。
- 28天内87例(1.4%)住院或死于SARS-CoV-2感染(索托维单抗组32例,莫诺拉韦组55例)。
- 调整后索托维单抗较莫诺拉韦的HR为0.54(95%CI 0.33-0.88,P=0.01);倾向评分加权模型HR为0.50(95%CI 0.31-0.81,P=0.005)。
- 完全接种人群中HR为0.53(95%CI 0.31-0.90,P=0.02);2022年2月16日至5月1日奥密克戎BA.2流行期探索性分析结果相似。
关键数值与推荐
- 主要结局为治疗开始后28天内因新冠住院(新冠为主要诊断)或死于新冠(新冠为根本或 contributory 死因)。
- 索托维单抗组28天内住院或死亡32例,莫诺拉韦组55例;总事件率1.4%。
临床怎么用
- 对于社区高危新冠成人患者,索托维单抗在预防重症结局方面可能优于莫诺拉韦。
- 研究结果支持在常规诊疗中优先考虑索托维单抗用于该人群,但需结合当地药物可及性与变异株流行情况。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients infected with SARS-CoV-2 in the community and at high risk of severe outcomes from covid-19. DESIGN: Observational cohort study with the OpenSAFELY platform. SETTING: With the approval of NHS England, a real world cohort study was conducted with the OpenSAFELY-TPP platform (a secure, transparent, open source software platform for analysis of NHS electronic health records), and patient level electronic health record data were obtained from 24 million people registered with a general practice in England that uses TPP software. The primary care data were securely linked with data on SARS-CoV-2 infection and treatments, hospital admission, and death, over a period when both drug treatments were frequently prescribed in community settings. PARTICIPANTS: Adult patients with covid-19 in the community at high risk of severe outcomes from covid-19, treated with sotrovimab or molnupiravir from 16 December 2021. INTERVENTIONS: Sotrovimab or molnupiravir given in the community by covid-19 medicine delivery units. MAIN OUTCOME MEASURES: Admission to hospital with covid-19 (ie, with covid-19 as the primary diagnosis) or death from covid-19 (ie, with covid-19 as the underlying or contributing cause of death) within 28 days of the start of treatment. RESULTS: Between 16 December 2021 and 10 February 2022, 3331 and 2689 patients were treated with sotrovimab and molnupiravir, respectively, with no substantial differences in baseline characteristics. Mean age of all 6020 patients was 52 (standard deviation 16) years; 59% were women, 89% were white, and 88% had received three or more covid-19 vaccinations. Within 28 days of the start of treatment, 87 (1.4%) patients were admitted to hospital or died of infection from SARS-CoV-2 (32 treated with sotrovimab and 55 with molnupiravir). Cox proportional hazards models stratified by area showed that after adjusting for demographic information, high risk cohort categories, vaccination status, calendar time, body mass index, and other comorbidities, treatment with sotrovimab was associated with a substantially lower risk than treatment with molnupiravir (hazard ratio 0.54, 95% confidence interval 0.33 to 0.88, P=0.01). Consistent results were found from propensity score weighted Cox models (0.50, 0.31 to 0.81, P=0.005) and when restricted to people who were fully vaccinated (0.53, 0.31 to 0.90, P=0.02). No substantial effect modifications by other characteristics were detected (all P values for interaction >0.10). The findings were similar in an exploratory analysis of patients treated between 16 February and 1 May 2022 when omicron BA.2 was the predominant variant in England. CONCLUSIONS: In routine care of adult patients in England with covid-19 in the community, at high risk of severe outcomes from covid-19, those who received sotrovimab were at lower risk of severe outcomes of covid-19 than those treated with molnupiravir.
引用
- Zheng B, Green ACA, Tazare J, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ. 2022. PMID: 36384890. doi:10.1136/bmj-2022-071932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。